Table 3. Changes in anti-IAV-specific IgG production in untreated patients and patients treated with OSV and ZNV for 5 days, with or without CAM.

Treatment	n	IgG concentration						Percentage of patients with ≥1-fold and ≥4-fold increases in anti-IAV-specific IgG concentration during treatment
		Anti-IAV-specific IgG (U/mL)				Total IgG (mg/mL)
		H1N1		H3N2				H1N1		H3N2
		Before	After	Before	After	Before	After	≥1-fold (After/before)	≥4-fold (After/before)	≥1-fold (After/before)	≥4-fold (After/before)
No treatment	49	0.5 (0.2–0.9)	0.8 (0.4–1.5)¶	0.4 (0.2–0.7)	0.8 (0.3–1.4)¶	19.3 (10.9–48.3)	17.7 (10.2–28.1)*	73.5	30.6	73.5	34.7
OSV	52	0.2 (0.03–0.7)	0.5 (0.06–1.0)	0.2 (0.04–0.5)	0.4 (0.06–1.1)¶	13.2 (9.1–17.6)	11.8 (8.6–17.4)	63.5	21.2	75.0	32.7
OSV+CAM	14	0.5 (0.3–0.6)	0.9 (0.5–1.4)¶	0.5 (0.2–0.5)	0.6 (0.4–1.2)*	14.1 (10.1–21.1)	12.0 (9.6–16.7)	78.6	21.4	85.7	14.3
ZNV	22	0.6 (0.3–1.1)	0.6 (0.4–1.1)	0.3 (0.2–0.5)	0.5 (0.4–0.9)¶	11.9 (8.3–31.4)	15.3 (9.4–28.4)	40.9‡	13.6	68.2	18.2
ZNV+CAM	8	0.3 (0.2–0.6)	0.9 (0.2–1.8)*	0.4 (0.2–0.7)	1.4 (0.4–2.6)*	15.4 (10.2–22.0)	12.0 (8.9–14.9)	100.0†	25.0	100.0#	50.0

Data are median (interquartile range). Before and after denote before and after treatment, respectively.

*P<0.05,

^¶ P<0.01, versus before treatment for the same parameter (Wilcoxon signed-ranks test).

^‡ P<0.01, versus the respective no treatment (Fisher's exact test).

^# P<0.06 to <0.09, versus the ZNV group (Fisher's exact test).

^† P<0.01, versus the ZNV group (Fisher's exact test).